Atezolizumab Plus nab-Paclitaxel and Carboplatin FDA Approved for Metastatic NSCLC

Atezolizumab (Tecentriq®, Genentech Inc.) in combination with nab-paclitaxel and carboplatin is now FDA approved as first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations. Atezolizumab, previously approved to treat extensive-stage small cell lung cancer, metastatic urothelial carcinoma, and metastatic triple-negative breast cancer, works as a monoclonal antibody and stimulates the immune system by block...
Continue reading

Osimertinib for EGFR-Mutated Advanced NSCLC: An Interview with Suresh S. Ramalingam, MD

The treatment of advanced-stage non-small cell lung cancer (NSCLC) has improved steadily in the past few years, and individualized therapy for patients with mutations in the epidermal growth factor receptor (EGFR) is applied in routine clinical practice. While EGFR-mutated NSCLC is effectively treated with tyrosine kinase inhibitors (TKIs) such as erlotinib or gefitinib, there is a need to develop more effective treatments to improve outcomes in these patients. In a study now published in The Ne...
Continue reading

The Deadly Consequences of Fine Particle Air Pollution

A new study finds an association between fine particulate matter (PM2.5) air pollution and deaths from nine different causes, including cardiovascular disease, cerebrovascular disease, hypertension, dementia, and lung cancer, among others. Furthermore, 99% of PM2.5-associated deaths were linked to levels of PM2.5 exposure currently deemed acceptable by US Environmental Protection Agency (EPA) recommendations.Atmospheric particulate matter with a diameter of less than 2.5 micrometers, PM2.5, is p...
Continue reading

Racial, Age-Related Disparities in Lung Cancer Treatment

A new study reports that only 62.1% of US patients with lung cancer receive treatment that adheres to guidelines, and elderly and non-Hispanic black patients are disproportionately represented among those whose cancer is undertreated.For the study, now published in Annals of the American Thoracic Society, the researchers evaluated whether 441,812 lung cancer cases in the US National Cancer Database diagnosed between 2010 and 2014 received treatment that adhered to the National Comprehensive Canc...
Continue reading

Yogurt and Fiber Intake May Reduce Lung Cancer Risk

Researchers have discovered that consuming more dietary fiber and yogurt decreases an individual's chance of developing lung cancer. Yogurt, a probiotic food, and dietary fiber, a huge source of prebiotics, offer many health benefits by modulating the gut microbiota and metabolic pathways."Our findings have no immediate clinical impacts on [patients with] lung cancer, but do have a major public health impact on lung cancer prevention," stated lead researcher, Xiao-Ou Shu, MD, PhD, Professor of M...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.